| Name | Title | Contact Details |
|---|
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.
Ventana Medical Systems is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake`s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau.
Avalon Pharmaceuticals , Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.